A metabolic shift toward the formation of proproliferative estrogen metabolites, including 16αOHE1, by altered expression of CYP1B1, is associated with the development and progression of PAH.1 Although CYP1B1 expression is low under basal conditions, expression is upregulated in PAH. Here, CYP1B1 is linked to pulmonary arterial hypertension.